Akiyoshi Komuro

Medicine · Health Sciences

15h-index2.0kcitations71works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pancreatic and Hepatic Oncology Research(21), Epigenetics and DNA Methylation(12), Cancer Genomics and Diagnostics(12), Cancer Diagnosis and Treatment(10), Colorectal Cancer Treatments and Studies(9)

Publications71 total

Supplementary Tables 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2025Open Access
Supplementary Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2025Open Access
Supplementary Figures 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2025Open Access
Vgll2 as an integrative regulator of mitochondrial function and contractility specific to skeletal muscle
Journal of Cellular Physiology·2024· 3 cited
Correction: Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer
Cell Death and Disease·2024· 1 citedOpen Access
Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer
Cell Death and Disease·2024· 13 citedOpen Access
Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Figures 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Tables 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Tables 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Figures 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Figures 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Figures 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Data from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Tables 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
Supplementary Tables 1-4 from MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Kohei Miyazono(30), Mitsunobu R. Kano(22), Yasuyuki Morishita(21), Kunihiko Kiyono(20), Caname Iwata(18), Hitoshi Okada(18), Takeshi Ueda(16), Masahiko Honda(14), Masakazu Yashiro(13), Kosei Hirakawa(13), H. Amano(13), Suman Dash(13), Masako Oka(11), Michio Kaminishi(10), Hiroshi Suzuki(10), Masahito Kawazu(10), Erik Johansson(8), Hironori Matsuyama(7), Koichi Sugimoto(7), Hiroyuki Aburatani(6)